S-1: Cadrenal Therapeutics Files S-1 for Warrant Resale

Cadrenal Therapeutics filed an S-1 registration statement for the resale of 428,227 common shares underlying warrants from a recent private placement and registered direct offering.

Summary

• The filing registers 428,227 shares of common stock for resale by Selling Stockholders, consisting of 414,748 shares from Common Warrants and 13,479 shares from Placement Agent Warrants.
• The Common Warrants were issued to investors in a private placement that closed on December 16, 2025, while Placement Agent Warrants were issued to H.C. Wainwright & Co., LLC as compensation.
• The company will not receive proceeds from the sale of these shares by Selling Stockholders, but will receive proceeds from any cash exercise of the warrants, intended for working capital and general corporate purposes.
• Cadrenal Therapeutics' common stock is listed on the Nasdaq Capital Market under the symbol CVKD, with a closing price of $7.535 per share on December 22, 2025.
• A recent Registered Direct Offering and concurrent Private Placement on December 15, 2025, raised approximately $2.2 million in gross proceeds, with an offering price of $10.85 per share.
• Common Warrants have an exercise price of $10.60 per share, and Placement Agent Warrants have an exercise price of $13.5625 per share.
• The company acquired VLX-1005 and related assets from Veralox Therapeutics Inc. on December 10, 2025, expanding its clinical-stage pipeline.
• Net tangible book value as of September 30, 2025, was approximately $2.7 million ($1.33 per share), increasing to an as adjusted pro forma net tangible book value of $10.1 million ($3.64 per share) assuming full warrant exercise.

Sentiment

Score: 3

Explanation: The filing highlights significant financial instability, including limited operating capital, an explicit 'going concern' warning, and the necessity for substantial future funding without firm commitments. While the company has an active clinical pipeline, the immediate and substantial dilution for investors and the high financial risk factors outweigh the positive developments.

Positives

• Successfully completed a Registered Direct Offering and concurrent Private Placement, raising approximately $2.2 million in gross proceeds.
• Acquired VLX-1005 and related assets from Veralox Therapeutics Inc., adding a first-in-class Phase 2 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT) to the pipeline.
• Possesses a pipeline of three clinical-stage assets: VLX-1005 for HIT, tecarfarin (a warfarin replacement) for chronic anticoagulation in high-risk patients, and frunexian (a first-in-class IV Factor XIa inhibitor) for acute hospital settings.
• Will receive proceeds from the cash exercise of Common Warrants and Placement Agent Warrants, which will be used for working capital and general corporate purposes.

Negatives

• The company has limited available operating capital and will require additional capital shortly after the current offering, with no commitments for future financing.
• Future issuance of securities may dilute existing investors' equity ownership and depress the market price of the common stock.
• The registration of 428,227 shares for resale is significant relative to the 2,338,127 outstanding shares, potentially causing the market price to fall.
• Purchasers in this offering will experience immediate and substantial dilution in net tangible book value, specifically $6.96 per Common Warrant Share and $9.9225 per Placement Agent Warrant Share.
• The company does not expect to pay dividends in the foreseeable future, requiring investors to rely solely on stock appreciation for returns.
• Product candidates are in clinical development and have not been approved by regulatory agencies, with no guarantee of future approval or marketability.

Risks

• Limited available operating capital and the necessity to raise additional capital shortly after the current offering, with no assurance of obtaining financing on acceptable terms or at all.
• Substantial doubt about the company's ability to continue as a going concern if required capital cannot be raised, potentially leading to a curtailment of business objectives.
• Resales of a significant number of Common Stock shares (428,227) by Selling Stockholders could adversely affect the market price and the company's ability to raise equity capital.
• Future issuances of additional shares or convertible debt securities could result in substantial dilution to existing stockholders.
• Immediate and substantial dilution in net tangible book value for investors purchasing shares in this offering.
• Management has broad discretion over the use of proceeds from warrant exercises, which may not necessarily enhance operating results or the stock price.
• The company does not anticipate paying cash dividends in the foreseeable future, meaning investors must rely on stock appreciation for any return.
• Product candidates are in clinical development and have not been approved by the FDA or European Commission, and may never be approved or marketed.

Future Outlook

The company intends to use proceeds from any cash exercise of Common Warrants and Placement Agent Warrants for working capital and general corporate purposes. It expects to require additional capital for clinical trials until its operations generate sufficient revenue to cover expenses. The company's current product candidates are undergoing clinical development and have not been approved by regulatory agencies, with no guarantee of future approval or marketability.

Management Comments

• "We intend to use the net proceeds from this offering for working capital and general corporate purposes."
• "Our management will have broad discretion over the use of proceeds, if any, from this offering resulting from any cash exercise of Common Warrants or Placement Agent Warrants."
• "We expect to require additional capital for clinical trials until our operations generate sufficient revenue to cover our expenses."
• "We have never declared or paid cash dividends on the Common Stock and do not anticipate paying cash dividends on the Common Stock in the foreseeable future."

Industry Context

Cadrenal Therapeutics operates in the biotechnology and pharmaceutical industry, focusing on developing novel and differentiated products for acute and chronic anticoagulation management in rare and high-risk patient populations. Its pipeline includes VLX-1005 (a 12-LOX inhibitor for HIT), tecarfarin (a warfarin replacement for kidney dysfunction/LVAD patients), and frunexian (an IV Factor XIa inhibitor for acute care). These candidates aim to address critical unmet needs and improve upon existing treatments, positioning the company in specialized niches within the broader cardiovascular and hematology therapeutic areas, emphasizing innovation in complex medical challenges.

Comparison to Industry Standards

• Tecarfarin is designed as a 'warfarin replacement' to overcome metabolic factors that make warfarin less reliable, suggesting a potential improvement over a long-established industry standard anticoagulant.
• Frunexian is highlighted as the 'only intravenous FXIa inhibitor in clinical development targeting purely the acute/critical care hospital setting,' indicating a unique market position compared to other Factor XIa inhibitors or acute anticoagulants.
• VLX-1005 targets heparin-induced thrombocytopenia (HIT), a severe complication of heparin, which is the 'most commonly used parenteral anticoagulant,' aiming to provide a solution where current options may be insufficient or problematic.

Management Changes

Corporate Governance

Related Party Transactions

• H.C. Wainwright & Co., LLC (Placement Agent) received a 7.0% cash fee and a 1% management fee of the gross proceeds from the December 2025 Offering, plus $10,000 for non-accountable expenses and $10,000 for clearing fees.
• H.C. Wainwright & Co., LLC also received Placement Agent Warrants to purchase 13,479 shares of Common Stock in the December 2025 Offering.
• Wainwright served as sales agent for an At The Market Offering Agreement, receiving 3.0% of gross sales price.
• Wainwright received a 7.0% cash fee and reimbursement of expenses/legal fees for the November 2024 Warrant Inducement, plus 2024 PA Warrants for 18,571 shares.
• Wainwright received a 7.5% cash fee (25% paid to a financial advisor), a 1.0% management fee, and reimbursement of expenses/legal fees for the July 2023 Private Placement, plus 2023 PA Warrants for 18,572 shares.
• Certain Selling Stockholders (Augustus Trading LLC, Noam Rubinstein, Charles Worthman, Wilson Drive Holdings LLC) are affiliated with H.C. Wainwright & Co., LLC.
• HESP LLC received 40,000 shares of Common Stock on January 19, 2023, pursuant to an amendment to an Asset Purchase Agreement.
• Consultants received shares of Common Stock or restricted common stock for services on March 30, 2023 (722 shares), March 31, 2023 (5,156 shares), September 11, 2024 (13,333 shares), October 10, 2024 (25,000 shares), January 8, 2025 (25,000 shares), and June 26, 2025 (10,000 shares).
• Stock options were issued to officers and directors on January 23, 2025.

Stakeholder Impact

• **Shareholders:** Face potential significant dilution from the resale of 428,227 shares and future capital raises. Existing shareholders may see their ownership percentage decrease and stock price potentially depressed. Investors purchasing in this offering will experience immediate and substantial dilution in net tangible book value. No dividends are expected in the foreseeable future.
• **Employees/Management:** Management and directors received stock options and are subject to lock-up agreements for 10 days post-offering. Indemnification provisions aim to protect directors and officers from certain liabilities.
• **Creditors:** The explicit 'going concern' warning and continuous need for additional capital could impact the company's creditworthiness and ability to meet future obligations if not successfully addressed.
• **Customers/Patients (future):** Continued funding is crucial for the clinical development of product candidates (VLX-1005, tecarfarin, frunexian). Successful development could offer novel treatments for high-risk patient populations, but failure to secure funding poses a risk to these programs.

Next Steps

• File a further amendment to the registration statement to declare it effective.
• Keep the registration statement effective until no holder owns any Common Warrants or Common Warrant Shares.
• Use proceeds from any cash exercise of Common Warrants and Placement Agent Warrants for working capital and general corporate purposes.
• Continue clinical development of VLX-1005, tecarfarin, and frunexian.
• Seek additional funding for clinical trials and ongoing operations.

Key Dates

Recommendation

The filing raises substantial doubt about the company's ability to continue as a going concern due to limited operating capital and the need for significant additional funding without firm commitments. This fundamental financial instability, coupled with immediate and substantial dilution for new investors and the potential for further dilution, presents an extremely high-risk profile. The lack of expected dividends further reduces investor appeal, making the stock highly speculative with significant downside risk.

Keywords

Cadrenal Therapeutics, CVKD, S-1, Registration Statement, Common Stock, Warrants, Private Placement, Registered Direct Offering, Resale, Dilution, Anticoagulation, VLX-1005, Heparin-Induced Thrombocytopenia, HIT, Tecarfarin, Frunexian, Factor XIa inhibitor, Nasdaq, Biotechnology, Pharmaceutical, Clinical Stage